Description: Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Home Page: www.genocea.com
GNCA Technical Analysis
100 Acorn Park Drive
Cambridge,
MA
02140
United States
Phone:
617 876 8191
Officers
| Name | Title |
|---|---|
| Mr. William D. Clark M.B.A. | Pres, CEO & Director |
| Dr. Jessica Baker Flechtner Ph.D. | Chief Scientific Officer |
| Ms. Diantha Duvall CPA, M.B.A. | CFO & Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0095 |
| Price-to-Sales TTM: | 0.12 |
| IPO Date: | 2014-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |